| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Amit Munshi is Director at ZURA, with reported holdings spanning 4 companies. Amit Munshi's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.5M at current prices.
Our model assigns Amit Munshi a below-average insider score of 37/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -38.4%.
Amit Munshi's largest disclosed position is in ZURA as Director, worth about $3.1M. Net of sales, the ZURA filings show accumulation of 277,391 shares.
Amit Munshi has 25 Form 4 filings on record from June 2017 to June 2026, across 5 companies: Director at Inhibikase Therapeutics (IKT), 2024–2026; Director at Zura Bio (ZURA), 2023–2026; Director at Arcutis Biotherapeutics (ARQT), 2025–2026, and 2 more.
The 32 reported transactions were 24 option or other derivative awards, 3 stock awards, 3 open-market purchases and 1 disposition back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $1.5M and no sales.
The largest open-market purchase was 365,000 shares of IKT at an average $1.37 on October 21, 2024, about $500K. Twelve months later IKT was down 29%.